FDA and Machine Learning: What Regulated Companies Need to Know in 2026

The FDA has moved decisively into the machine learning era. From the agency's evolving guidance on AI/ML-enabled medical devices to its growing scrutiny of machine learning models in drug development, 2026 marks a turning point for regulated companies.

If your organization uses — or plans to use — machine learning in any FDA-regulated process, this is what you need to know right now.

The FDA's Machine Learning Landscape

The FDA's approach to machine learning has matured considerably. Three major developments are shaping the regulatory landscape:

1. Predetermined Change Control Plans (PCCPs)

The FDA's final guidance on PCCPs for AI/ML-enabled devices establishes how manufacturers can modify algorithms post-market without requiring new 510(k) submissions for every update. This is a game-changer — but it comes with stringent requirements:

• Transparency: You must describe the types of changes your ML model may undergo
• Validation protocols: Pre-specified testing and performance monitoring plans
• Risk controls: Guardrails that trigger human review when model performance degrades

Companies that proactively build PCCP-ready documentation into their quality systems will have a significant competitive advantage.

2. Good Machine Learning Practice (GMLP)

The FDA's 10 guiding principles for GMLP — developed jointly with Health Canada and the UK MHRA — are becoming the de facto standard for ML lifecycle management in healthcare. These principles cover:

• Multi-disciplinary expertise in design and development
• Representative datasets with appropriate training/tuning/testing splits
• Independent reference standards for model evaluation
• Ongoing monitoring of deployed models in real-world settings
• Security and resilience of AI systems

3. Real-World Evidence from ML Models

The FDA is increasingly open to real-world evidence (RWE) derived from ML models — but only when the underlying data governance and model validation are rigorous. The agency has made clear that:

• Training data provenance must be fully documented
• Model drift detection must be continuous, not periodic
• Bias testing must span demographic subgroups relevant to the intended use

What This Means for Your Organization

If You Manufacture Medical Devices

The Software as a Medical Device (SaMD) framework now expects ML-specific controls. Your quality management system (QMS) needs:

• Design controls that account for ML model training, validation, and deployment
• Risk analysis that specifically addresses algorithmic bias, data quality, and model degradation
• Post-market surveillance that includes automated performance monitoring

If you already maintain ISO 13485 certification, you have a strong foundation — but ML-specific extensions are non-negotiable.

If You Operate in Pharma or Biotech

ML is transforming drug discovery, clinical trial design, and manufacturing process optimization. The FDA expects:

• Validated computational models: Any ML model used in a regulatory submission must meet the same validation standards as traditional analytical methods
• Transparent methodology: Black-box models without explainability features will face increasing regulatory pushback
• GxP compliance: ML systems in GMP environments must comply with 21 CFR Part 11 (electronic records) and Annex 11 equivalents

If You Are in Clinical Research

ML-driven patient stratification, endpoint prediction, and adverse event detection are all accelerating. The FDA's guidance on adaptive and decentralized clinical trials creates new opportunities — but also new compliance obligations around data integrity and model governance.

The AI Governance Connection

Here is the critical insight most organizations miss: FDA machine learning compliance is not just a technical problem — it is a governance problem.

Without a structured AI governance framework, your ML initiatives will face:

• Fragmented oversight across quality, regulatory, and data science teams
• Inconsistent model validation practices
• Undocumented decision-making in model development
• Audit vulnerabilities when inspectors ask "who approved this model?"

This is exactly where frameworks like ISO 42001 (AI Management Systems) and the NIST AI Risk Management Framework intersect with FDA expectations. An integrated approach — where AI governance wraps around your existing QMS — creates both compliance efficiency and competitive differentiation.

Action Steps for 2026

1. Audit your ML inventory: Catalog every machine learning model in your organization, including those in development. Classify each by regulatory impact.

2. Map to FDA guidance: For each model, identify which FDA guidance documents apply (PCCP, GMLP, SaMD framework, RWE guidance).

3. Integrate AI governance: Implement a cross-functional AI governance committee with representation from quality, regulatory affairs, data science, and legal.

4. Build validation pipelines: Establish automated, reproducible model validation workflows that generate the documentation the FDA expects.

5. Prepare for inspection: FDA investigators are increasingly trained on AI/ML topics. Your readiness should include staff who can explain model architecture, training data decisions, and monitoring protocols to a non-technical auditor.

How We Can Help

At Regulated AI Consulting, we specialize in the intersection of AI governance and regulatory compliance. Our AI Risk Assessment service helps you identify ML-related compliance gaps, while our AI Governance Design engagements build the management systems needed to sustain compliance over time.

If your organization is navigating FDA expectations around machine learning, schedule a consultation to discuss your specific situation.